A Connecticut pharmaceutical company has been hit with its second class action lawsuit in as many months over claims it defrauded stockholders with shady sales practices and by falsely hyping the growth of its drug Soliris, a treatment that costs $455,000 a year.

The Boston Retirement System filed the federal lawsuit in New Haven Dec. 29 on behalf of thousands of investors against Alexion Pharmaceuticals Inc. The federal securities class action is being brought on behalf of anyone who purchased Alexion securities between Feb. 10, 2014, and Dec. 9, 2016.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]